Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALL_CART: CAR-T for r/r ALL in Children and Young Adults
NCT06709469Phase 1Recruiting
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of AUTO1/22 and CYAD-101 in B cell acute lymphoblastic leukemia (B-ALL) and t-cell acute lymphoblastic leukemia (T-ALL) (2 arms), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Incidence and severity of adverse events at 5 years. Started Jul 2025; status: recruiting.
02
Drugs
AUTO1/22CYAD-101
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06709469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709469.